360° SearchNetwork Hot Spots Trends Time Series

Publication: PharmCast

First reported 8 hours ago - Updated 8 hours ago - 1 reports

Compositions and methods for silencing genes involved in hemorrhagic fever

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target Lassa virus (LASV) or tissue factor (TF) gene expression, lipid particles comprising one or more (e.g., a ... [Published PharmCast - 8 hours ago]

Entities: RNA, Nucleotide, sirna

First reported 8 hours ago - Updated 8 hours ago - 1 reports

Long lasting drug formulations

The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably ... [Published PharmCast - 8 hours ago]

Entities: Nucleic Acid, Polypeptide, Vector, Ribonucleic Acid

First reported Jun 16 2013 - Updated Jun 16 2013 - 1 reports

Human lysosomal protein and methods of its use

The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. ... [Published PharmCast - Jun 16 2013]

Entities: DNA, Nucleic Acid, Protein

First reported Jun 16 2013 - Updated Jun 16 2013 - 1 reports

Tissue targeted complement modulators

Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement ... [Published PharmCast - Jun 16 2013]

Entities: Nucleotide, Moiety, Nucleic Acid, Amino Acid

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Compounds for inhibiting protein aggregation, and methods for making and using them

The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, ... [Published PharmCast - Jun 14 2013]

Entities: Invention, Peptide, Polypeptide, Protein

First reported Jun 11 2013 - Updated Jun 11 2013 - 1 reports

Long-acting growth hormone and methods of producing same

Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of ... [Published PharmCast - Jun 11 2013]

Entities: Human Growth Hormone, Polypeptide, Amino Acid, Peptide, Invention

First reported Jun 09 2013 - Updated Jun 09 2013 - 1 reports

Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin

Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed.Description of ... [Published PharmCast - Jun 09 2013]

Entities: Strontium, Cation, Topical Product, Invention, Calcium

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

Tyrosine-modified recombinant rAAV vector compositions and methods for use

Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein ... [Published PharmCast - Jun 06 2013]

Entities: vectors, Nucleic Acid, Capsid

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

CCR ligands for stem cell homing

Chemokines ligands to at least one of CCR1, CCR2, CCR3, or CCR5 can be used to home stem cells for therapeutic applications.Description of the InventionFIELD OF THE INVENTIONThe present invention relates to chemokines and particularly to use of chemokines ... [Published PharmCast - Jun 06 2013]

Entities: Nucleic Acid, Ligand, Stem Cell

First reported Jun 04 2013 - Updated Jun 04 2013 - 2 reports

Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety

The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.Description of the InventionFIELD OF THE INVENTIONThe ... [Published PharmCast - Jun 04 2013]

Entities: Nucleic Acid, Antigen, Encipher

First reported May 23 2013 - Updated May 23 2013 - 2 reports

Gene polymorphisms predictive for dual TKI therapy

The invention provides compositions and methods for determining the likelihood of successful treatment with dual therapy such as lapatinib. The methods comprise determining the genomic polymorphism or expression level of a gene present in a predetermined ... [Published PharmCast - May 23 2013]

Entities: Nucleic Acid, polymorphism, Nucleotide

First reported May 21 2013 - Updated May 22 2013 - 2 reports

Therapeutic use of anti-CS1 antibodies

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The ... [Published PharmCast - May 22 2013]

Entities: Antibody, Nucleic Acid, Protein

Quotes

...increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., "Expression of ribozymes in gene transfertransfer systems to modulate target RNA levels." Curr Opin Biotechnol. 1998 October; 9(5):486-96]...

Long lasting drug formulations [Published PharmCast - 8 hours ago]

...Mol. Cell. Biol. 6:2872-2883 (1986); Haj-Ahmad et al., J Virology 57:267-274 (1986); Davidson et al., J Virology 61:1226-1239 (1987); Zhang "Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis" BioTechniques 15:868-872 (1993))...

Tissue targeted complement modulators [Published PharmCast - Jun 16 2013]

...An example of a recombinant adenovirus is a "gutless, "high-capacity", or "helper-dependent" adenovirus vector. Such a vector features, for example, (1) the deletion of all or most viral-coding sequences (those sequences encoding viral proteins), (2) the viral inverted terminal repeats (ITRs) which are sequences required for viral DNADNA replication, (3) up to 28-32 kb of "exogenous" or "heterologous" sequences (e g., sequences encoding MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MIP-1.alpha., MIP-1.beta., and/or MIP-2), and (4) the viral DNA packaging sequence which is required for packaging of the viral genomes into infectious capsids. For specifically myocardial cells, variants of such recombinant adenoviral vectors can contain tissue-specific (e g., cardiomyoctye) enhancers and promoters operably linked to a chemokine ligand gene (e g., MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MIP-1.alpha., MIP-1.beta., and/or MIP-2 gene)."

CCR ligands for stem cell homing [Published PharmCast - Jun 06 2013]

Yet other sequencing methods are disclosed, e g., in U S Pat. No. 5,580,732 entitled "Method of DNA Sequencing Employing A Mixed DNA-Polymer Chain Probe" and U S Pat. No. 5,571,676 entitled "Method For Mismatch-Directed In Vitro DNA Sequencing."

Gene polymorphisms predictive for dual TKI therapy [Published PharmCast - May 23 2013]

More Content

sort by: Date \| Relevance
Long lasting drug formulations [Published PharmCast - 8 hours ago]
Compositions and methods for silencing genes in... [Published PharmCast - 8 hours ago]
Human lysosomal protein and methods of its use [Published PharmCast - Jun 16 2013]
Tissue targeted complement modulators [Published PharmCast - Jun 16 2013]
Compounds for inhibiting protein aggregation, a... [Published PharmCast - Jun 14 2013]
Long-acting growth hormone and methods of produ... [Published PharmCast - Jun 11 2013]
Methods for inhibiting sensory nerves by topica... [Published PharmCast - Jun 09 2013]
Tyrosine-modified recombinant rAAV vector compo... [Published PharmCast - Jun 06 2013]
CCR ligands for stem cell homing [Published PharmCast - Jun 06 2013]
Neutrophil-depleted platelet rich plasma formul... [Published PharmCast - Jun 04 2013]
Regulated expression of antigen and/or regulate... [Published PharmCast - Jun 04 2013]
Chimeric vaccines [Published PharmCast - Jun 04 2013]
Compositions and methods that enhance an immune... [Published PharmCast - Jun 02 2013]
Dendrimer conjugates [Published PharmCast - Jun 02 2013]
Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoi... [Published PharmCast - May 31 2013]
Riboswitches, methods for their use, and compos... [Published PharmCast - May 29 2013]
Platelet rich plasma formulations for cardiac t... [Published PharmCast - May 29 2013]
Gene polymorphisms predictive for dual TKI therapy [Published PharmCast - May 23 2013]
Fish vaccine [Published PharmCast - May 23 2013]
Therapeutic use of anti-CS1 antibodies [Published PharmCast - May 22 2013]
Humanized C-kit antibody [Published PharmCast - May 21 2013]
System and method for synchronizing image seque... [Published PharmCast - May 01 2013]
Gastrin releasing peptide compounds [Published PharmCast - Apr 30 2013]
Recombinant polyprotein vaccines for the treatm... [Published PharmCast - Apr 18 2013]
Animal product free system and process for puri... [Published PharmCast - Apr 18 2013]
Multi plasmids system for the production of inf... [Published PharmCast - Apr 17 2013]
Compositions and methods for inhibiting express... [Published PharmCast - Apr 16 2013]
Drug delivery through hydrogel plugs [Published PharmCast - Apr 16 2013]
Methods to predict risk for celiac disease by d... [Published PharmCast - Apr 15 2013]
Human monoclonal antibodies against Bacillus an... [Published PharmCast - Apr 09 2013]